{"pmid":32473905,"title":"Challenges of diabetes care management in developing countries with a high incidence of COVID-19: A brief report.","text":["Challenges of diabetes care management in developing countries with a high incidence of COVID-19: A brief report.","BACKGROUND AND AIMS: Diabetes mellitus (DM) is one of the most critical risk factors for complications and death in COVID-19 patients. The present study aims to highlight challenges in the management of diabetic patients during the COVID-19 outbreak in developing countries. METHODS: We reviewed the literature to obtain information about diabetic care during the Covid-19 crisis. We also seek opinions of clinicians working in undeveloped countries. RESULTS: Current challenges faced by clinicians in the management of diabetic patients in developing countries are as follows: lack of preventive measures, inadequate number of visits, loss of the traditional method of communication with the patient, shortage of medications, impaired routine diabetic care, and absence of telehealth services. CONCLUSIONS: Developing countries are faced with many challenges in diabetes management due to a lack of resources.","Diabetes Metab Syndr","Nouhjah, Sedigheh","Jahanfar, Shayesteh","32473905"],"abstract":["BACKGROUND AND AIMS: Diabetes mellitus (DM) is one of the most critical risk factors for complications and death in COVID-19 patients. The present study aims to highlight challenges in the management of diabetic patients during the COVID-19 outbreak in developing countries. METHODS: We reviewed the literature to obtain information about diabetic care during the Covid-19 crisis. We also seek opinions of clinicians working in undeveloped countries. RESULTS: Current challenges faced by clinicians in the management of diabetic patients in developing countries are as follows: lack of preventive measures, inadequate number of visits, loss of the traditional method of communication with the patient, shortage of medications, impaired routine diabetic care, and absence of telehealth services. CONCLUSIONS: Developing countries are faced with many challenges in diabetes management due to a lack of resources."],"journal":"Diabetes Metab Syndr","authors":["Nouhjah, Sedigheh","Jahanfar, Shayesteh"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473905","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.dsx.2020.05.012","keywords":["covid-19","challenges","developing countries","diabetes care","management"],"topics":["Prevention"],"weight":1,"_version_":1668341932706758657,"score":9.490897,"similar":[{"pmid":32311652,"pmcid":"PMC7194953","title":"Diabetes self-management amid COVID-19 pandemic.","text":["Diabetes self-management amid COVID-19 pandemic.","BACKGROUND AND AIMS: COVID-19 pandemic has challenged the physician-centered approach of diabetes care in India that is primarily based on routine clinic visits. We aim to review the various aspects of patient-centered care via diabetes self-management education based on available literature. METHODS: This is a narrative review using Pubmed, EMBASE and Google Scholar search till March 29, 2020. Search terms were \"COVID-19\", \"diabetes self-care\", \"diabetes self-management education\", \"DSME\", \"diabetes self-management in India\", \"diabetes self-care in India\" and \"DSME in India\". RESULTS: We have discussed an educational plan on diabetes self-management that can be adopted for people with diabetes mellitus in our country amid the ongoing pandemic. We have also identified the barriers to diabetes self-management in the current scenario and suggested possible solutions to overcome those. CONCLUSIONS: We have reemphasized the need for a simultaneous patient-centered approach in routine diabetes care that has to be coordinated by a multidisciplinary team amid the ongoing COVID-19 pandemic.","Diabetes Metab Syndr","Banerjee, Mainak","Chakraborty, Soumen","Pal, Rimesh","32311652"],"abstract":["BACKGROUND AND AIMS: COVID-19 pandemic has challenged the physician-centered approach of diabetes care in India that is primarily based on routine clinic visits. We aim to review the various aspects of patient-centered care via diabetes self-management education based on available literature. METHODS: This is a narrative review using Pubmed, EMBASE and Google Scholar search till March 29, 2020. Search terms were \"COVID-19\", \"diabetes self-care\", \"diabetes self-management education\", \"DSME\", \"diabetes self-management in India\", \"diabetes self-care in India\" and \"DSME in India\". RESULTS: We have discussed an educational plan on diabetes self-management that can be adopted for people with diabetes mellitus in our country amid the ongoing pandemic. We have also identified the barriers to diabetes self-management in the current scenario and suggested possible solutions to overcome those. CONCLUSIONS: We have reemphasized the need for a simultaneous patient-centered approach in routine diabetes care that has to be coordinated by a multidisciplinary team amid the ongoing COVID-19 pandemic."],"journal":"Diabetes Metab Syndr","authors":["Banerjee, Mainak","Chakraborty, Soumen","Pal, Rimesh"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311652","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.dsx.2020.04.013","keywords":["covid-19","dsme","diabetes mellitus","diabetes self-care","diabetes self-management education"],"locations":["India","India","India","India"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Prevention"],"weight":1,"_version_":1666138491275182080,"score":269.1542},{"pmid":32502693,"title":"The Australian response to the COVID-19 pandemic and diabetes - lessons learned.","text":["The Australian response to the COVID-19 pandemic and diabetes - lessons learned.","The COVID-19 pandemic has had a significant impact on the economy and health system of most countries in the world and this is also true of Australia. Australia has not seen the huge surge of COVID-19 positive cases and subsequent hospitalisations and deaths experienced in other parts of the world. However there have been important social and health strategies to \"flatten\" the curve, to reduce infections and to manage those infected. These have included closure of international and interstate borders, local lockdown measures, physical distancing, shift to work from home, closure of non-essential businesses and full or partial closure of all schools and tertiary education facilities. From the diabetes care perspective, there was a significant and concerted diversion of hospital resources and staff to COVID-19 specific activities. Reduced access to primary care, diagnostic and hospital services for diabetes, combined with fear of exposure to the virus in these settings, led to a significant drop in access to usual diabetes care. Provision of outpatient and private sector diabetes services via telehealth was encouraged and supported by expanded and new government subsidies. Importantly, for the first time, there was government funded subsidy for care delivered via the telephone and inclusion of credentialled diabetes educators in funded telephone/telehealth support. The Australian health professional and consumer organisations worked cooperatively producing guidelines, position statements and other educational resources specific for the COVID-19 setting. Once the COVID-19 pandemic is over, review of all the changes will be important, determining which should be permanently implemented. The learnings from COVID-19 should help prepare Australia for future pandemics or other major health crises.","Diabetes Res Clin Pract","Andrikopoulos, Sof","Johnson, Greg","32502693"],"abstract":["The COVID-19 pandemic has had a significant impact on the economy and health system of most countries in the world and this is also true of Australia. Australia has not seen the huge surge of COVID-19 positive cases and subsequent hospitalisations and deaths experienced in other parts of the world. However there have been important social and health strategies to \"flatten\" the curve, to reduce infections and to manage those infected. These have included closure of international and interstate borders, local lockdown measures, physical distancing, shift to work from home, closure of non-essential businesses and full or partial closure of all schools and tertiary education facilities. From the diabetes care perspective, there was a significant and concerted diversion of hospital resources and staff to COVID-19 specific activities. Reduced access to primary care, diagnostic and hospital services for diabetes, combined with fear of exposure to the virus in these settings, led to a significant drop in access to usual diabetes care. Provision of outpatient and private sector diabetes services via telehealth was encouraged and supported by expanded and new government subsidies. Importantly, for the first time, there was government funded subsidy for care delivered via the telephone and inclusion of credentialled diabetes educators in funded telephone/telehealth support. The Australian health professional and consumer organisations worked cooperatively producing guidelines, position statements and other educational resources specific for the COVID-19 setting. Once the COVID-19 pandemic is over, review of all the changes will be important, determining which should be permanently implemented. The learnings from COVID-19 should help prepare Australia for future pandemics or other major health crises."],"journal":"Diabetes Res Clin Pract","authors":["Andrikopoulos, Sof","Johnson, Greg"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502693","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.diabres.2020.108246","keywords":["australia","covid-19","diabetes care"],"locations":["Australia","Australia","Australian","Australia","Australian"],"countries":["Australia"],"countries_codes":["AUS|Australia"],"topics":["Prevention"],"weight":1,"_version_":1668804508688318464,"score":246.27046},{"pmid":32407746,"pmcid":"PMC7214308","title":"Prevalence of diabetes mellitus in 2019 novel coronavirus: a Meta-analysis.","text":["Prevalence of diabetes mellitus in 2019 novel coronavirus: a Meta-analysis.","BACKGROUND: Since December 2019, a new strain ofcoronavirus named 2019 novel coronavirus (2019-nCoV) has been discovered in Wuhan. The prevalence of diabetes mellitus, which is a great public health issue leading to immunity inhibition and anincreased incidenceofinfections, has been increasing over the past ten years. The aim of this research was to systematically assess the prevalence of diabetes mellitus among 2019-nCoV. METHODS: We searched PubMed, Embase, Web of Science and Medline for observational studies up to February 25, 2020. A random effects model or fixed-effects model was applied to evaluate the pooled prevalence of diabetes mellitus and odds ratio (OR) with 95% confidence interval (CI). FINDINGS: In total, nine papers met the eligibility criteria. The pooled prevalence of DM was 9% (95% CI 6%-12%). There was obvious heterogeneity (I(2) 65%, p=0.004) in the prevalence of DM in these studies. The prevalence of DM in moderate patients with 2019-nCoV was 7% (95% CI 4%-10%). The prevalence of DM in severe patients with 2019-nCoV was 17% (95% CI 13%-21%). The prevalence of DM in severe patients with 2019-nCoV was significantly higher than that in moderate patients with 2019-nCoV (OR 2.49, 95% CI 1.70 to 3.64). INTERPRETATION: To our knowledge, this work is the first report showing the prevalence of diabetes mellitus in patients with 2019-nCoV, which is beneficial to prevent the spread of 2019-nCoV in the future.","Diabetes Res Clin Pract","Wang, Xiang","Wang, Shoujun","Sun, Liangge","Qin, Guijun","32407746"],"abstract":["BACKGROUND: Since December 2019, a new strain ofcoronavirus named 2019 novel coronavirus (2019-nCoV) has been discovered in Wuhan. The prevalence of diabetes mellitus, which is a great public health issue leading to immunity inhibition and anincreased incidenceofinfections, has been increasing over the past ten years. The aim of this research was to systematically assess the prevalence of diabetes mellitus among 2019-nCoV. METHODS: We searched PubMed, Embase, Web of Science and Medline for observational studies up to February 25, 2020. A random effects model or fixed-effects model was applied to evaluate the pooled prevalence of diabetes mellitus and odds ratio (OR) with 95% confidence interval (CI). FINDINGS: In total, nine papers met the eligibility criteria. The pooled prevalence of DM was 9% (95% CI 6%-12%). There was obvious heterogeneity (I(2) 65%, p=0.004) in the prevalence of DM in these studies. The prevalence of DM in moderate patients with 2019-nCoV was 7% (95% CI 4%-10%). The prevalence of DM in severe patients with 2019-nCoV was 17% (95% CI 13%-21%). The prevalence of DM in severe patients with 2019-nCoV was significantly higher than that in moderate patients with 2019-nCoV (OR 2.49, 95% CI 1.70 to 3.64). INTERPRETATION: To our knowledge, this work is the first report showing the prevalence of diabetes mellitus in patients with 2019-nCoV, which is beneficial to prevent the spread of 2019-nCoV in the future."],"journal":"Diabetes Res Clin Pract","authors":["Wang, Xiang","Wang, Shoujun","Sun, Liangge","Qin, Guijun"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407746","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabres.2020.108200","keywords":["2019 novel coronavirus","diabetes mellitus","meta-analysis","prevalence"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666950579806535681,"score":219.68433},{"pmid":32405783,"title":"Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.","text":["Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.","The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes.","Diabetologia","Katulanda, Prasad","Dissanayake, Harsha A","Ranathunga, Ishara","Ratnasamy, Vithiya","Wijewickrama, Piyumi S A","Yogendranathan, Nilukshana","Gamage, Kavinga K K","de Silva, Nipun L","Sumanatilleke, Manilka","Somasundaram, Noel P","Matthews, David R","32405783"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes."],"journal":"Diabetologia","authors":["Katulanda, Prasad","Dissanayake, Harsha A","Ranathunga, Ishara","Ratnasamy, Vithiya","Wijewickrama, Piyumi S A","Yogendranathan, Nilukshana","Gamage, Kavinga K K","de Silva, Nipun L","Sumanatilleke, Manilka","Somasundaram, Noel P","Matthews, David R"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405783","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s00125-020-05164-x","keywords":["covid-19","coronavirus","diabetes","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1666802845436870656,"score":211.336},{"pmid":32447101,"title":"Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports.","text":["Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports.","Diabetes mellitus is challenging in the context of the COVID-19 pandemic. The prevalence of diabetes patients hospitalized in intensive care units for COVID-19 is two- to threefold higher, and the mortality rate at least double, than that of non-diabetes patients. As the population with diabetes is highly heterogeneous, it is of major interest to determine the risk factors of progression to a more serious life-threatening COVID-19 infection. This brief review discusses the main findings of CORONADO, a prospective observational study in France that specifically addressed this issue as well as related observations from other countries, mainly China and the US. Some prognostic factors beyond old age have been identified: for example, an increased body mass index is a major risk factor for requiring respiratory assistance. Indeed, obesity combines several risk factors, including impaired respiratory mechanics, the presence of other comorbidities and inappropriate inflammatory responses, partly due to ectopic fat deposits. While previous diabetic microvascular (renal) and macrovascular complications also increase risk of death, the quality of past glucose control had no independent influence on hospitalized diabetes patient outcomes, and whether the quality of glucose control might modulate risk of COVID-19 in non-hospitalized diabetes patients is still unknown. In addition, no negative signs regarding the use of RAAS blockers and DPP-4 inhibitors and outcomes of COVID-19 could be identified. Hyperglycaemia at the time of hospital admission is associated with poor outcomes, but it may simply be considered a marker of severity of the infection. Thus, the impact of glucose control during hospitalization on outcomes related to COVID-19, which was not investigated in the CORONADO study, is certainly deserving of specific investigation.","Diabetes Metab","Scheen, Andre J","Marre, Michel","Thivolet, Charles","32447101"],"abstract":["Diabetes mellitus is challenging in the context of the COVID-19 pandemic. The prevalence of diabetes patients hospitalized in intensive care units for COVID-19 is two- to threefold higher, and the mortality rate at least double, than that of non-diabetes patients. As the population with diabetes is highly heterogeneous, it is of major interest to determine the risk factors of progression to a more serious life-threatening COVID-19 infection. This brief review discusses the main findings of CORONADO, a prospective observational study in France that specifically addressed this issue as well as related observations from other countries, mainly China and the US. Some prognostic factors beyond old age have been identified: for example, an increased body mass index is a major risk factor for requiring respiratory assistance. Indeed, obesity combines several risk factors, including impaired respiratory mechanics, the presence of other comorbidities and inappropriate inflammatory responses, partly due to ectopic fat deposits. While previous diabetic microvascular (renal) and macrovascular complications also increase risk of death, the quality of past glucose control had no independent influence on hospitalized diabetes patient outcomes, and whether the quality of glucose control might modulate risk of COVID-19 in non-hospitalized diabetes patients is still unknown. In addition, no negative signs regarding the use of RAAS blockers and DPP-4 inhibitors and outcomes of COVID-19 could be identified. Hyperglycaemia at the time of hospital admission is associated with poor outcomes, but it may simply be considered a marker of severity of the infection. Thus, the impact of glucose control during hospitalization on outcomes related to COVID-19, which was not investigated in the CORONADO study, is certainly deserving of specific investigation."],"journal":"Diabetes Metab","authors":["Scheen, Andre J","Marre, Michel","Thivolet, Charles"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447101","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.diabet.2020.05.008","keywords":["diabetic complications","glucose control","mechanical ventilation","mortality","obesity","sars-cov-2"],"locations":["France","China","US"],"countries":["France","United States","China"],"countries_codes":["FRA|France","USA|United States","CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667698385913643010,"score":207.7419}]}